The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S1206: A dose-finding study of veliparib (ABT-888) added to chemoradiotherapy (CRT) with carboplatin (C) and paclitaxel (P) for unresectable stage III non-small cell lung cancer (NSCLC).
 
Mihaela C. Cristea
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Trovagene
 
Jieling Miao
No Relationships to Disclose
 
Athanassios Argiris
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - Genentech/Roche
 
Allen M. Chen
No Relationships to Disclose
 
Megan Eileen Daly
No Relationships to Disclose
 
Roy H. Decker
Research Funding - 21st Century Oncology; Merck
Travel, Accommodations, Expenses - Physicans' Education Resource
 
Linda L. Garland
No Relationships to Disclose
 
Ding Wang
No Relationships to Disclose
 
Marianna Koczywas
No Relationships to Disclose
 
James Moon
No Relationships to Disclose
 
Karen Kelly
Honoraria - Bristol-Myers Squibb; Roche
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Lilly; Synta
Research Funding - Abbvie (Inst); Celgene (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Millennium (Inst); Novartis (Inst); Synta (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Lilly; Roche; Synta
 
David R. Gandara
Honoraria - Array BioPharma; AstraZeneca; Celgene; Lilly; Novartis; Synta
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer; Response Genetics; Sanofi; Synta
Research Funding - Abbott Laboratories (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); ImClone Systems (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biomarin; Boehringer Ingelheim; Dava Oncology; Pfizer